» Articles » PMID: 34903846

Salivary Gland Dysfunction and Salivary Redox Imbalance in Patients with Alzheimer's Disease

Overview
Journal Sci Rep
Specialty Science
Date 2021 Dec 14
PMID 34903846
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is associated with the deposition of β-amyloid in the brain. AD accounts for over 50% of cases of dementia which results from disturbances in redox homeostasis. Indeed, increased intensity of protein oxidation and nitration as well as lipid peroxidation is observed in brain areas with considerable amounts of amyloid plaques and neurofibrillary tangles. However, little is known about the oxidoreductive balance of salivary glands in AD patients. Therefore, the aim of this study was to evaluate the antioxidant barrier and oxidative/nitrosative stress biomarkers in stimulated saliva and blood of AD patients. The study was participated by 25 AD patients and 25 non-demented controls without neurological diseases or cognitive impairment, matched by age and gender to the study group. The number of patients was determined based on a previous pilot study (test power = 0.9). We found a significant decrease in the activity of erythrocyte superoxide dismutase (SOD) and glutathione peroxidase (GPx), increased activity of catalase (CAT) and reduced concentration of plasma non-enzymatic antioxidants (uric acid, UA and reduced glutathione, GSH). In contrast, in the stimulated saliva of AD patients we observed significantly decreased activity of all antioxidant enzymes (SOD, CAT and GPx) as well as concentration of GSH compared to the control group. The content of lipid (malondialdehyde, MDA) and protein (advanced oxidation protein products, AOPP; advanced glycation end-products, AGE) oxidation products as well as biomarkers of nitrosative stress (peroxynitrite, nitrotyrosine) was significantly higher in both saliva and plasma of AD patients compared to the controls. In AD patients, we also observed a considerable decrease in stimulated saliva secretion and salivary total protein content, and an increase in salivary β-amyloid concentration. In conclusion, AD results in redox imbalance towards oxidative reactions, both at the level of the oral cavity and the entire body. General redox balance disturbances do not coincide with salivary redox balance disturbances. Reduction in stimulated saliva secretion in AD patients reflects secretory dysfunction of the parotid glands.

Citing Articles

An Update of Salivary Biomarkers for the Diagnosis of Alzheimer's Disease.

Guo H, Yang R, Cheng W, Li Q, Du M Int J Mol Sci. 2025; 26(5).

PMID: 40076682 PMC: 11900270. DOI: 10.3390/ijms26052059.


Impact of 16S rRNA on Intestinal Flora Alterations and Early Diagnosis in Early Alzheimer's Disease Patients.

Lv D, Lin X, Zhang X, Shen Q Actas Esp Psiquiatr. 2025; 53(2):208-221.

PMID: 40071377 PMC: 11898251. DOI: 10.62641/aep.v53i2.1682.


Xerogenic medications may contribute to decreased unstimulated salivary flow in patients with oral burning and/or gastro-esophageal reflux disease.

Sangalli L, Eldomiaty W, Miller C Front Dent Med. 2025; 4:1047235.

PMID: 39916932 PMC: 11797851. DOI: 10.3389/fdmed.2023.1047235.


Multi-Omics Assessment of Puff Volume-Mediated Salivary Biomarkers of Metal Exposure and Oxidative Injury Associated with Electronic Nicotine Delivery Systems.

He X, Meister M, Jeon J, Shinde A, Zhang Q, Chepaitis P Environ Health Perspect. 2025; 133(1):17005.

PMID: 39819025 PMC: 11737583. DOI: 10.1289/EHP14321.


Guidelines for the standardization of pre-analytical variables for salivary biomarker studies in Alzheimer's disease research: An updated review and consensus of the Salivary Biomarkers for Dementia Research Working Group.

Ng T, Udeh-Momoh C, Lim M, Gleerup H, Leifert W, Ajalo C Alzheimers Dement. 2024; 21(2):e14420.

PMID: 39737743 PMC: 11848381. DOI: 10.1002/alz.14420.


References
1.
Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

2.
Buege J, Aust S . Microsomal lipid peroxidation. Methods Enzymol. 1978; 52:302-10. DOI: 10.1016/s0076-6879(78)52032-6. View

3.
Kalousova M, Skrha J, Zima T . Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2003; 51(6):597-604. View

4.
Baldone D, Pruitt K, Rahemtulla F . Specific assays for peroxidases in human saliva. Arch Oral Biol. 1986; 31(10):661-8. DOI: 10.1016/0003-9969(86)90095-6. View

5.
Adamczyk-Sowa M, Bieszczad-Bedrejczuk E, Galiniak S, Rozmilowska I, Czyzewski D, Bartosz G . Oxidative modifications of blood serum proteins in myasthenia gravis. J Neuroimmunol. 2017; 305:145-153. DOI: 10.1016/j.jneuroim.2017.01.019. View